MMP9 and colorectal cancer: Andecaliximab, a fully humanized antibody against MMP-9, showed anti-tumoral effect in a colorectal cancer preclinical assay [337], and is currently under evaluation in phase II in combination with immunotherapy (NCT02864381) and phase III with chemotherapy (NCT02545504) for gastric or gastroesophageal junction (GEJ) adenocarcinoma patients.